Compound muscle action potential as an early functional in vivo measure of Sarm1 inhibition after sciatic nerve transection.
Hur SK, Leahey RR, Geringer M, Cho CH, Hernandez-Barry H, Pang J, Sawyer WS, Baca M, Nespi M, Asuncion RR, Choy M, Maksymetz J, Vito ST, Imperio J, Stark K, Green SA, Chan BK, Xie L, Ly J, Nugent AA, Hofmann JW, Hinz FI, Weber M.
J Neuropathol Exp Neurol. 2025 Nov 1;84(11):998-1012. doi: 10.1093/jnen/nlaf066.
PMID:40478524
Site-dependent thenar compound muscle action potential: Comparison between surface and needle recordings.
Yue S, Yue Q, Hale T, Knecht A.
J Back Musculoskelet Rehabil. 2019;32(6):841-845. doi: 10.3233/BMR-181188.
PMID:30883332
A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (Onasemnogene Abeparvovec) SMA therapy.
Barrois R, Barnerias C, Deladrière E, Leloup-Germa V, Tervil B, Audic F, Boulay C, Cances C, Cintas P, Davion JB, Espil-Taris C, Manel V, Pereon Y, Piarroux J, Quijano Roy S, Vuillerot C, Walther-Louvier U, Desguerre I, Gitiaux C.
Neuromuscul Disord. 2023 Apr;33(4):309-314. doi: 10.1016/j.nmd.2023.02.004. Epub 2023 Feb 11.